Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NEW YORK, April 7, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that preclinical data for TGR-1202, the Company's novel PI3k delta inhibitor will be highlighted at...
-
NEW YORK, March 11, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), today announced it has priced an underwritten sale of 2,702,809 shares of its common stock at $6.71 per share, the...
-
NEW YORK, March 10, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael Weiss, the Company's Interim Chief Executive Officer, will be presenting at the 26th...
-
NEW YORK, March 5, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization...
-
NEW YORK, March 4, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company, today announced that a conference call will be held on...
-
NEW YORK, Feb. 7, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael Weiss, the Company's Interim Chief Executive Officer, will be presenting at the 16th Annual...
-
NEW YORK, Jan. 13, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael Weiss, the Company's Interim Chief Executive Officer, will be presenting at the 32nd Annual...
-
All evaluable CLL patients treated with once daily TGR-1202 at 800 mg exhibited significant nodal reductions with 3 of 4 patients achieving > 50% nodal partial response TGR-1202 appears...
-
NEW YORK, Dec. 6, 2013 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company today announced that it has initiated a multi-center Phase 2...
-
NEW YORK, Dec. 5, 2013 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that the following abstracts for TGR-1202, the Company's PI3K delta inhibitor, have been selected for...